MedTrace Logo

Honey & Nigella Sativa Trial Against COVID-19

NCT04347382 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 313

Last updated 2020-11-12

No results posted yet for this study

Summary

To evaluate the effectiveness of Nigella Sativa and honey stirred in 250 ml of distilled water 12 hourly till patient becomes asymptomatic or a maximum of 14 days with standard hospital care versus standard hospital care alone with placebo capsule and 250 ml water, in clearing the COVID-19 nucleic acid from throat and nasal swab, lowering disease detrimental effects on HRCT chest/X-ray and severity of symptoms along with duration of hospital stay till day 14th day of follow up and 30 days mortality (primary outcomes).

Conditions

  • Coronavirus Infection
  • Sars-CoV2

Interventions

DRUG

Honey

1gm/Kg/Day

DRUG

Nigella Sativa / Black Cumin

80mg/Kg/day

DRUG

Placebos

Empty capsule with 250ml of distilled water

Sponsors & Collaborators

  • Sohaib Ashraf

    lead OTHER

Principal Investigators

  • Shoaib Ashraf, PhD · Massachusetts General Hospital, Harvard Medical School, USA

  • Muhammad Ashraf, DVM, PhD · University Of Veterinary & Animal Sciences, Lahore

  • Sohaib Ashraf, MBBS · Federal Post-Graduate Medical Institute, Lahore

  • Muhammad Ahmad Imran, MBBS · Shaikh Zayed Hospital, Lahore

  • Ayesha Hamayun, MBBS, PhD · Shaikh Khalifa Bin Zayed Al-Nahyan Medical & Dental College, Lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-08-30
Completion
2020-08-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347382 on ClinicalTrials.gov